Pharmanutra SpA
MIL:PHN
Intrinsic Value
Pharmanutra SpA develops nutraceutical products and medical devices. [ Read More ]
The intrinsic value of one PHN stock under the Base Case scenario is 38.53 EUR. Compared to the current market price of 47.15 EUR, Pharmanutra SpA is Overvalued by 18%.
Valuation Backtest
Pharmanutra SpA
Run backtest to discover the historical profit from buying and selling PHN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pharmanutra SpA
Current Assets | 58.7m |
Cash & Short-Term Investments | 6.2m |
Receivables | 22.7m |
Other Current Assets | 29.7m |
Non-Current Assets | 53.8m |
Long-Term Investments | 297k |
PP&E | 26.4m |
Intangibles | 22.5m |
Other Non-Current Assets | 4.6m |
Current Liabilities | 27.6m |
Accounts Payable | 13.7m |
Accrued Liabilities | 3.4m |
Short-Term Debt | 627k |
Other Current Liabilities | 10m |
Non-Current Liabilities | 30.4m |
Long-Term Debt | 23.4m |
Other Non-Current Liabilities | 7m |
Earnings Waterfall
Pharmanutra SpA
Revenue
|
100.2m
EUR
|
Cost of Revenue
|
-2.4m
EUR
|
Gross Profit
|
97.8m
EUR
|
Operating Expenses
|
-74.4m
EUR
|
Operating Income
|
23.4m
EUR
|
Other Expenses
|
-10.6m
EUR
|
Net Income
|
12.8m
EUR
|
Free Cash Flow Analysis
Pharmanutra SpA
PHN Profitability Score
Profitability Due Diligence
Pharmanutra SpA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Pharmanutra SpA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
PHN Solvency Score
Solvency Due Diligence
Pharmanutra SpA's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Pharmanutra SpA's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHN Price Targets Summary
Pharmanutra SpA
According to Wall Street analysts, the average 1-year price target for PHN is 82.28 EUR with a low forecast of 77.77 EUR and a high forecast of 90.3 EUR.
Shareholder Return
PHN Price
Pharmanutra SpA
Average Annual Return | 47.35% |
Standard Deviation of Annual Returns | 47.72% |
Max Drawdown | -41% |
Market Capitalization | 453.3m EUR |
Shares Outstanding | 9 681 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one PHN stock under the Base Case scenario is 38.53 EUR.
Compared to the current market price of 47.15 EUR, Pharmanutra SpA is Overvalued by 18%.